AU2001255488B2 - Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies - Google Patents

Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies Download PDF

Info

Publication number
AU2001255488B2
AU2001255488B2 AU2001255488A AU2001255488A AU2001255488B2 AU 2001255488 B2 AU2001255488 B2 AU 2001255488B2 AU 2001255488 A AU2001255488 A AU 2001255488A AU 2001255488 A AU2001255488 A AU 2001255488A AU 2001255488 B2 AU2001255488 B2 AU 2001255488B2
Authority
AU
Australia
Prior art keywords
agonist
rar
receptor
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2001255488A
Other languages
English (en)
Other versions
AU2001255488A1 (en
Inventor
Roshantha A Chandraratna
Maurizio Pacifici
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
University of Pennsylvania
Original Assignee
Allergan Inc
University of Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc, University of Pennsylvania filed Critical Allergan Inc
Publication of AU2001255488A1 publication Critical patent/AU2001255488A1/en
Application granted granted Critical
Publication of AU2001255488B2 publication Critical patent/AU2001255488B2/en
Assigned to THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, ALLERGAN, INC. reassignment THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Request for Assignment Assignors: ALLERGAN, INC.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
AU2001255488A 2000-04-20 2001-04-19 Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies Ceased AU2001255488B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/552,823 2000-04-20
US09/552,823 US20030114482A1 (en) 1999-12-15 2000-04-20 Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
PCT/US2001/012742 WO2001080894A2 (en) 2000-04-20 2001-04-19 Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2006233216A Division AU2006233216A1 (en) 2000-04-20 2006-10-27 Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies

Publications (2)

Publication Number Publication Date
AU2001255488A1 AU2001255488A1 (en) 2002-01-24
AU2001255488B2 true AU2001255488B2 (en) 2006-07-27

Family

ID=24206947

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2001255488A Ceased AU2001255488B2 (en) 2000-04-20 2001-04-19 Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
AU5548801A Pending AU5548801A (en) 2000-04-20 2001-04-19 Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
AU2006233216A Abandoned AU2006233216A1 (en) 2000-04-20 2006-10-27 Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU5548801A Pending AU5548801A (en) 2000-04-20 2001-04-19 Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
AU2006233216A Abandoned AU2006233216A1 (en) 2000-04-20 2006-10-27 Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies

Country Status (9)

Country Link
US (1) US20030114482A1 (enExample)
EP (1) EP1274456B1 (enExample)
JP (1) JP2003531180A (enExample)
AT (1) ATE285794T1 (enExample)
AU (3) AU2001255488B2 (enExample)
CA (1) CA2407021A1 (enExample)
DE (1) DE60108094T2 (enExample)
HK (1) HK1053053B (enExample)
WO (1) WO2001080894A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1701934B1 (en) * 2003-12-26 2009-02-25 Allergan, Inc. DISUBSTITUTED CHALCONE OXIMES HAVING RAR(Gamma)-RETINOID RECEPTOR ANTAGONIST ACTIVITY
JP2007070281A (ja) * 2005-09-06 2007-03-22 Matsumoto Shika Univ レチノイドｘ受容体関連化合物を用いた骨粗鬆症の治療剤
US8680153B2 (en) * 2005-12-13 2014-03-25 The Royal Institution For The Advancement Of Learning/Mcgill University Method for correcting a lipid imbalance in a subject
US20090209601A1 (en) * 2008-02-15 2009-08-20 Wyeth Use of rxr agonists for the treatment of osteoarthritis
CN111773213B (zh) 2010-09-01 2023-02-24 托马斯杰弗逊大学 用于肌肉修复和再生的组合物和方法
US20140094512A1 (en) * 2012-10-02 2014-04-03 Nikolas Gunkel Method of modulating the degree of adipose tissue deposited intramuscularly
WO2014073209A1 (ja) 2012-11-08 2014-05-15 国立大学法人山口大学 角結膜障害の治療剤
US9480739B2 (en) 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
US10702502B2 (en) 2013-05-22 2020-07-07 Yamaguchi University Inhibitor for retinochoroidal disorders
ES2963348T3 (es) 2016-06-08 2024-03-26 Clementia Pharmaceuticals Inc Métodos para tratar la osificación heterotópica
JP7018957B2 (ja) 2016-11-16 2022-02-14 クレメンティア ファーマシューティカルズ インコーポレイテッド 多発性骨軟骨腫（ｍｏ）を処置するための方法
AU2018300150A1 (en) 2017-07-11 2020-01-30 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020146612A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4621100A (en) * 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
US5977125A (en) * 1994-10-31 1999-11-02 Eisai Co., Ltd. Mono-or polyenic carboxylic acid derivatives
US5514825A (en) * 1994-12-29 1996-05-07 Allergan, Inc. Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
US5648514A (en) * 1994-12-29 1997-07-15 Allergan Substituted acetylenes having retinoid-like biological activity
DE19501032A1 (de) * 1995-01-14 1996-07-18 Max Delbrueck Centrum Mittel zur Behandlung von rheumatischen Erkrankungen
US5776699A (en) * 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
US5877207A (en) * 1996-03-11 1999-03-02 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
KR100485642B1 (ko) * 1996-03-18 2005-09-30 에자이 가부시키가이샤 축합고리함유카르복실산유도체
US5808124A (en) * 1996-06-21 1998-09-15 Allergan O- or S-substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5773594A (en) * 1996-06-21 1998-06-30 Allergan Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5763635A (en) * 1996-06-21 1998-06-09 Allergan Tetrahydronaphthalene derivatives substituted in the 8 position with alkyhidene groups having retinoid and/or retinoid antagonist-like biological activity
US5739338A (en) * 1996-11-05 1998-04-14 Allergan N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity
US5728846A (en) * 1996-12-12 1998-03-17 Allergan Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives
US5760276A (en) * 1997-03-06 1998-06-02 Allergan Aryl-and heteroarylcyclohexenyl substituted alkenes having retinoid agonist, antagonist or inverse agonist type biological activity
US5962707A (en) * 1998-08-18 1999-10-05 Wisconsin Alumni Research Foundation 19-nor-vitamin D3 compounds with calcemic activity
CA2254429A1 (en) * 1998-11-19 2000-05-19 Tully Michael Underhill Compositions for promoting chondrogenesis
DE19910246A1 (de) * 1999-03-08 2000-09-28 Bayer Ag Trennfreundliche Polyurethan-Formschaum-Systeme
CA2402413A1 (en) * 2000-03-14 2001-09-20 The University Of Western Ontario Compositions and methods for affecting osteogenesis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
References cited in WO 01/80894 *

Also Published As

Publication number Publication date
DE60108094T2 (de) 2005-12-15
WO2001080894A3 (en) 2002-07-25
AU5548801A (en) 2001-11-07
HK1053053A1 (en) 2003-10-10
HK1053053B (en) 2005-06-10
JP2003531180A (ja) 2003-10-21
EP1274456B1 (en) 2004-12-29
US20030114482A1 (en) 2003-06-19
WO2001080894A2 (en) 2001-11-01
DE60108094D1 (de) 2005-02-03
EP1274456A2 (en) 2003-01-15
CA2407021A1 (en) 2001-11-01
ATE285794T1 (de) 2005-01-15
AU2006233216A1 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
AU784189B2 (en) Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
Derfoul et al. Glucosamine promotes chondrogenic phenotype in both chondrocytes and mesenchymal stem cells and inhibits MMP-13 expression and matrix degradation
US7608281B2 (en) Composition and use of RAR antagonists for promoting chondrogenesis
US20030114482A1 (en) Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
US9987296B2 (en) Compositions including anthocyanin or anthocyanidin for the prevention or treatment of Articular cartilage-associated conditions
JP2003522107A (ja) 骨成長および毛成長を刺激するためのプロテアソーム活性のインヒビター
AU2001255488A1 (en) Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
Wu et al. Pachymic acid suppresses the inflammatory response of chondrocytes and alleviates the progression of osteoarthritis via regulating the Sirtuin 6/NF-κB signal axis
WO2002087620A1 (en) Chondrogenesis promoters
JP2001503446A (ja) 骨欠乏状態を治療するためのピペラジン誘導体
HK1089112A (en) Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
WO2018204621A1 (en) Compositions including protocatechuic acid for the prevention or treatment of osteoarthritis
Sampath et al. Gaining Insights To Understand The Anti-Inflammatory Functions of Mesenchymal Stem Cell-Derived Conditioned Medium In Combination With Stigmasterol In IL-1β-Stimulated Rat Articular Chondrocytes–An In-Vitro Approach
CN119818518A (zh) 升麻素苷在制备促进成软骨分化药物及治疗软骨损伤疾病药物中的应用

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ALLERGAN, INC.; THE TRUSTEES OF THE UNIVERSITY OF

Free format text: FORMER APPLICANT(S): ALLERGAN, INC.

FGA Letters patent sealed or granted (standard patent)
GD Licence registered

Name of requester: VITAE PHARMACEUTICALS, INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired